Nanobody Chimeras Use Hepatitis B Antibodies to Fight Cancer

What is it about?

The study explored the feasibility of redirecting endogenous antihepatitis B virus (HBV) antibodies, generated by the HBV vaccine, towards cancer cells for immunotherapy. It involved engineering a bifunctional nanobody chimera, 7D12-HBsAg(99-169), which combined an anti-EGFR nanobody with an HBV surface antigen domain. The methodology demonstrated that these chimeras could effectively recruit anti-HBV antibodies onto cancer cell surfaces, triggering potent antibody-dependent cell-mediated phagocytosis and complement-dependent cytotoxicity, leading to the selective killing of EGFR-positive cancer cells. A xenograft mouse model was used to show that the 7D12-HBsAg(99-169) fusion significantly inhibited tumor growth by recruiting endogenous anti-HBV antibodies without inducing notable toxicity. The study established a proof-of-concept for leveraging endogenous antibodies induced by routine vaccination for cancer immunotherapy. It highlighted the potential to switch the antiviral immunity of naturally occurring polyclonal anti-HBV antibodies from vaccination to anticancer immunity.

Featured Image

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Why is it important?

This study is important as it presents an innovative approach to cancer immunotherapy by leveraging endogenous antibodies produced through routine vaccinations, such as the hepatitis B virus (HBV) vaccine, instead of relying on exogenous monoclonal antibodies (mAbs). This strategy addresses significant challenges associated with mAbs, including high production costs, limited accessibility, and potential immunogenicity. By redirecting naturally occurring antibodies to target cancer cells, the research offers a promising alternative that could enhance therapeutic efficacy while reducing side effects and broadening the scope of cancer treatments. Key Takeaways: 1. Novel Bifunctional Nanobody Chimera: The study successfully engineered a bifunctional nanobody chimera, 7D12-HBsAg(99-169), which effectively redirects endogenous anti-HBV antibodies to cancer cells, facilitating selective killing of EGFR-positive cancer cells through antibody-dependent cellular mechanisms. 2. Efficacy in Tumor Inhibition: The research demonstrated that the 7D12-HBsAg(99-169) fusion significantly inhibited tumor growth in a xenograft mouse model, leveraging endogenous anti-HBV antibodies without causing notable toxicity, indicating a potential for safe and effective cancer treatment. 3. Advancing Antitumor Immunity: By repurposing antiviral immunity into anticancer immunity, this study sets a precedent for using vaccine-induced antibodies in cancer immunotherapy, potentially expanding therapeutic options and improving outcomes for patients with EGFR-positive cancers.